FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175889295> ?p ?o ?g. }

• W3175889295 abstract "The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R-DLBCL) after second-line treatment failure is extremely poor. This study prospectively observed the efficacy and safety of decitabine with a modified cisplatin, cytarabine, and dexamethasone (DHAP) regimen in R/R-DLBCL patients who failed second-line treatment.Twenty-one R/R-DLBCL patients were enrolled and treated with decitabine and a modified DHAP regimen. The primary endpoints were overall response rate (ORR) and safety. The secondary endpoints were progression-free survival (PFS) and overall survival (OS).ORR reached 50% (complete response rate, 35%), five patients (25%) had stable disease (SD) with disease control rate (DCR) of 75%. Subgroup analysis revealed patients over fifty years old had a higher complete response rate compared to younger patients (P = 0.005), and relapsed patients had a better complete response rate than refractory patients (P = 0.031). Median PFS was 7 months (95% confidence interval, 5.1-8.9 months). Median OS was not achieved. One-year OS was 59.0% (95% CI, 35.5%-82.5%), and two-year OS was 51.6% (95% confidence interval, 26.9%-76.3%). The main adverse events (AEs) were grade 3/4 hematologic toxicities such as neutropenia (90%), anemia (50%), and thrombocytopenia (70%). Other main non-hematologic AEs were grade 1/2 nausea/vomiting (40%) and infection (50%). No renal toxicity or treatment-related death occurred.Decitabine with a modified DHAP regimen can improve the treatment response and prognosis of R/R-DLBCL patients with good tolerance to AEs, suggesting this regimen has potential as a possible new treatment option for R/R-DLBCL patients after second-line treatment failure.ClinicalTrials.gov, identifier: NCT03579082." @default.
• W3175889295 created "2021-07-05" @default.
• W3175889295 creator A5008465910 @default.
• W3175889295 creator A5015666587 @default.
• W3175889295 creator A5019544133 @default.
• W3175889295 creator A5022091246 @default.
• W3175889295 creator A5022526821 @default.
• W3175889295 creator A5047167996 @default.
• W3175889295 creator A5047718895 @default.
• W3175889295 creator A5048481277 @default.
• W3175889295 creator A5048995364 @default.
• W3175889295 creator A5050463501 @default.
• W3175889295 creator A5054709496 @default.
• W3175889295 creator A5057561820 @default.
• W3175889295 creator A5059119834 @default.
• W3175889295 creator A5062442835 @default.
• W3175889295 creator A5071798264 @default.
• W3175889295 creator A5072036342 @default.
• W3175889295 creator A5072861069 @default.
• W3175889295 creator A5076701232 @default.
• W3175889295 creator A5080214203 @default.
• W3175889295 creator A5083178617 @default.
• W3175889295 creator A5087936786 @default.
• W3175889295 creator A5091336301 @default.
• W3175889295 date "2021-06-18" @default.
• W3175889295 modified "2023-09-23" @default.
• W3175889295 title "Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure" @default.
• W3175889295 cites W1515568673 @default.
• W3175889295 cites W1905474624 @default.
• W3175889295 cites W1969461242 @default.
• W3175889295 cites W197652455 @default.
• W3175889295 cites W1986579589 @default.
• W3175889295 cites W1988466148 @default.
• W3175889295 cites W2002106466 @default.
• W3175889295 cites W2007757039 @default.
• W3175889295 cites W2016333491 @default.
• W3175889295 cites W2057201731 @default.
• W3175889295 cites W2079433846 @default.
• W3175889295 cites W2079906801 @default.
• W3175889295 cites W2086108274 @default.
• W3175889295 cites W2086695635 @default.
• W3175889295 cites W2106658124 @default.
• W3175889295 cites W2133201432 @default.
• W3175889295 cites W2140388731 @default.
• W3175889295 cites W2141476381 @default.
• W3175889295 cites W2150115389 @default.
• W3175889295 cites W2150587745 @default.
• W3175889295 cites W2151783390 @default.
• W3175889295 cites W2156665433 @default.
• W3175889295 cites W2168639163 @default.
• W3175889295 cites W2223160771 @default.
• W3175889295 cites W2305142474 @default.
• W3175889295 cites W2337581388 @default.
• W3175889295 cites W2338091757 @default.
• W3175889295 cites W2338193405 @default.
• W3175889295 cites W2492170142 @default.
• W3175889295 cites W2559431510 @default.
• W3175889295 cites W2598700764 @default.
• W3175889295 cites W2614852340 @default.
• W3175889295 cites W2737072798 @default.
• W3175889295 cites W2744261860 @default.
• W3175889295 cites W2782614891 @default.
• W3175889295 cites W2785209130 @default.
• W3175889295 cites W2913250620 @default.
• W3175889295 cites W2943432615 @default.
• W3175889295 cites W2959565564 @default.
• W3175889295 cites W2975799428 @default.
• W3175889295 cites W2977215371 @default.
• W3175889295 doi "https://doi.org/10.3389/fonc.2021.687374" @default.
• W3175889295 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8253157" @default.
• W3175889295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34222013" @default.
• W3175889295 hasPublicationYear "2021" @default.
• W3175889295 type Work @default.
• W3175889295 sameAs 3175889295 @default.
• W3175889295 citedByCount "8" @default.
• W3175889295 countsByYear W31758892952022 @default.
• W3175889295 countsByYear W31758892952023 @default.
• W3175889295 crossrefType "journal-article" @default.
• W3175889295 hasAuthorship W3175889295A5008465910 @default.
• W3175889295 hasAuthorship W3175889295A5015666587 @default.
• W3175889295 hasAuthorship W3175889295A5019544133 @default.
• W3175889295 hasAuthorship W3175889295A5022091246 @default.
• W3175889295 hasAuthorship W3175889295A5022526821 @default.
• W3175889295 hasAuthorship W3175889295A5047167996 @default.
• W3175889295 hasAuthorship W3175889295A5047718895 @default.
• W3175889295 hasAuthorship W3175889295A5048481277 @default.
• W3175889295 hasAuthorship W3175889295A5048995364 @default.
• W3175889295 hasAuthorship W3175889295A5050463501 @default.
• W3175889295 hasAuthorship W3175889295A5054709496 @default.
• W3175889295 hasAuthorship W3175889295A5057561820 @default.
• W3175889295 hasAuthorship W3175889295A5059119834 @default.
• W3175889295 hasAuthorship W3175889295A5062442835 @default.
• W3175889295 hasAuthorship W3175889295A5071798264 @default.
• W3175889295 hasAuthorship W3175889295A5072036342 @default.
• W3175889295 hasAuthorship W3175889295A5072861069 @default.
• W3175889295 hasAuthorship W3175889295A5076701232 @default.
• W3175889295 hasAuthorship W3175889295A5080214203 @default.
• W3175889295 hasAuthorship W3175889295A5083178617 @default.
• W3175889295 hasAuthorship W3175889295A5087936786 @default.
• W3175889295 hasAuthorship W3175889295A5091336301 @default.

• next